80,000 Shares in BioAge Labs, Inc. $BIOA Bought by Nano Cap New Millennium Growth Fund L P

Nano Cap New Millennium Growth Fund L P acquired a new position in shares of BioAge Labs, Inc. (NASDAQ:BIOA) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 80,000 shares of the company’s stock, valued at approximately $1,058,000. Nano Cap New Millennium Growth Fund L P owned approximately 0.22% of BioAge Labs as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs during the 3rd quarter worth about $27,000. CWM LLC lifted its holdings in shares of BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of BioAge Labs in the 2nd quarter valued at about $64,000. Finally, Bank of America Corp DE lifted its holdings in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares during the last quarter.

BioAge Labs Trading Up 3.9%

Shares of BIOA stock opened at $16.74 on Friday. The company has a market cap of $744.09 million, a price-to-earnings ratio of -6.97 and a beta of 0.99. The stock has a 50 day simple moving average of $17.82 and a 200-day simple moving average of $16.11. BioAge Labs, Inc. has a 12-month low of $3.79 and a 12-month high of $24.00.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The business had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, equities analysts forecast that BioAge Labs, Inc. will post -2.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. BTIG Research assumed coverage on BioAge Labs in a report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price for the company. Piper Sandler assumed coverage on BioAge Labs in a report on Tuesday, January 27th. They issued an “overweight” rating for the company. Oppenheimer assumed coverage on BioAge Labs in a report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 target price for the company. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BioAge Labs presently has an average rating of “Moderate Buy” and an average target price of $45.00.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.